Getz Pharma Pvt. Ltd.,in partnership withTabba Heart Institute, announced the launch of Pakistan Study of Premature Coronary Atherosclerosis in Young Adults (PAK- SEHAT)
Cardiovascular diseases continue to have a significant impact across the world among different populations. To address the issue of the rising health burden of ASCVD in Pakistan, Getz Pharma Pvt. Ltd and Tabba Heart Institute (THI) formally launched PAK-SEHAT- Pakistan Study of Premature Coronary Atherosclerosis in Young Adults, a nationwide study conducted through Pakistan’s first state of art mobile lab. PAK SEHAT project is the largest, first-of-its-kind, longitudinal cohort study on Atherosclerotic Risk Assessment in Pakistani Population. This 10-year joint venture of Getz Pharma &THI (PAK SEHAT) will help determine risk factors for coronary heart disease so that early detection can be done and disease can be prevented rather than treated.
Cardiovascular disease (CVD) is one of the leading causes of mortality worldwide, causing approximately 32% of annual deaths. The risk of cholesterol-associated CVD varies among different ethnicities; however, the risk is four fold in the South Asian (SA) Population compared to other races. Furthermore, almost 75% of all CVD deaths are in low and middle-income countries (LMIC), where there are finite health resources and a multitude of health-seeking barriers.
The state of heart diseases in Pakistan also reflects a concerning picture. According to the World Health Organization data published in 2018, coronary heart disease deaths in Pakistan reached 20% of total deaths, and Pakistan ranks 18 in cardiac mortality in the global ranking. Moreover, the numbers of potential CVD risk factors, including hypertension and diabetes, are also alarming in Pakistan, with 50% hypertension and 17.1% diabetes in the adult population. There is a drastic shift in CVD occurrence in young ages in the SA population, as evidenced by the groundbreaking INTERHEART study suggesting 10.6% of SA participants presented with a heart attack at <40 years of age. Therefore, this study primarily envisions screening the Pakistani individuals at a younger age to prevent increasing CVD burden in the future.
This study aims to recruit healthy volunteers <40 years of age, from selected urban and rural areas of Pakistan, who are asymptomatic and have no cardiovascular disease. This would allow for assessing the participants’ risk factor profiles and follow them up for at least five years to document the incidence of ASCVD. The objectives of PAK SEHAT includes:
1. To characterize the prevalence and severity of subclinical coronary atherosclerosis among young Pakistani men and women free of clinical CVD
2. To understand the impact, in terms of 5-year rates of cardiovascular events, by using the prognostic information provided by cardiac CTA and the other study tests and measurements to optimize cardiovascular prevention management in young Pakistanis.
While Pakistan is the second-most populous country in South Asia, most of the data on the prevalence of ASCVD from South Asian regions is derived from India. As a result, the Pakistani Population is highly underrepresented in global research, as there is currently no comprehensive database on the native Pakistani Population to assess the likelihood of developing ASCVD. Due to this high burden of disease, there is an urgent need for primary prevention and early screening for ASCVD in Pakistan.
The findings from a study of this scale can provide groundbreaking results. It would help in informing future health policy targeting the native Pakistani Population, and it would allow early interventions for patients with risk of ASCVD from a younger age. Getz Pharma and Tabba Heart Institute are proud to lead an initiative of this scale with the aim to contribute to the growing research database in Pakistan and promote early screening and prevention for cardiovascular diseases in the country.